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Background: Adjuvant chemotherapy after the resection of stage IB-IIIA non-small cell lung cancer (NSCLC) is now
the standard of care based on large-scale phase III trials and a meta-analysis. However, chemotherapy has plateaued
in terms of its efficacy, and the search for treatment prediction biomarkers is imperative for the further identification
of treatable subgroups. Therefore, we investigated the significance of cyclooxygenase-2 (Cox-2) expression and the
applicability of a Cox-2 inhibitor in patients who had received adjuvant chemotherapy.
Methods: We conducted a retrospective review of data from 97 patients who had received adjuvant chemotherapy.
The adjuvant chemotherapy consisted of an oral tegafur agent (OT) or platinum-based chemotherapy (PB). The
criteria for regimen selection were based on a discussion among the cancer board and enrollment in a clinical trial.
Immunohistochemical staining (IHC) for Cox-2 was performed, and the correlation between Cox-2 expression and
disease-free survival (DFS) was evaluated.
Results: IHC showed that 56 cases (57.7%) were positive for Cox-2. The rate of Cox-2 expression was similar for the PB
and OT groups. Among the patients who received PB, the DFS of the patients with Cox-2 expression was significantly
poorer than that of the patients without Cox-2 expression (P = 0.017), but there was no significant difference among
the patients who received OT (P = 0.617). In a multivariate analysis, Cox-2 expression and lymph node metastasis were
independent predictors of DFS among patients who received PB.
Conclusions: Cox-2 expression was a powerful predictor of DFS among patients who received PB as an adjuvant
chemotherapy. Further study investigating the use of a Cox-2 inhibitor for adjuvant chemotherapy is needed.
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Lung cancer is a leading cause of cancer-related death
worldwide. The most effective treatment of early-stage
non-small cell lung cancer (NSCLC) is surgical resec-
tion. In addition, adjuvant chemotherapy after the resec-
tion of stage II-IIIA NSCLC is now the standard of care
based on three large-scale phase III trials and an individ-
ual patient meta-analysis [1-4]. However, up to 60% of
patients with NSCLC with lymph node metastasis re-
lapse after surgery [5,6]. Currently, chemotherapy has* Correspondence: kshimizu@med.kawasaki-m.ac.jp
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unless otherwise stated.plateaued in terms of its efficacy, and the search for
treatment prediction biomarkers is imperative for the
further identification of treatable subgroups. For unre-
sectable advanced NSCLC, drug selection is usually de-
termined according to histological subtype and gene
mutation. The application of these methods to adjuvant
treatment is anticipated [7].
Cyclooxygenase (Cox) is the key enzyme required for
the conversion of arachidonic acid to prostaglandins
(PGs). Two Cox isoforms have been identified and are
referred to as constitutive Cox (Cox-1) and inducible
Cox (Cox-2); Cox-2 is an inducible enzyme that is acti-
vated in response to extracellular stimuli, such as growthl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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gators have demonstrated that Cox-2 is constitutively
overexpressed in a variety of epithelial malignancies,
such as lung, breast, pancreas, colon, esophagus, and
head and neck cancers, and Cox-2 overexpression is
usually associated with a poor prognosis [9-11]. Re-
cently, a clinical trial performed by Cancer and
Leukemia Group B demonstrated that Cox-2 expression
was a significant prognostic factor among patients with
advanced NSCLC receiving chemotherapy [12].
However, to our knowledge, the prognostic impact of
Cox-2 expression has not yet been investigated among
NSCLC patients who have received adjuvant chemother-
apy. In the present study, we investigated the signifi-
cance of Cox-2 expression among NSCLC patients who
have received adjuvant chemotherapy.Methods
Study population
We conducted this retrospective study in a total of 442
patients with NSCLC who underwent resection at the
Kawasaki Medical School Hospital between 2004 and
2010. Of these, 97 patients received adjuvant chemother-
apy and were enrolled in this study. None of the patients
had received either radiotherapy or chemotherapy prior
to surgery. The histological diagnosis of the tumors was
based on the criteria of the World Health Organization,
and the TNM stage was determined according to the
2009 criteria. Informed consent for the study of excised
tissue samples from the surgical specimens was obtained
from each patient. This study was conducted with the
approval of the institutional Ethics Committee of
Kawasaki Medical School (No.1417: Approved on
March 11, 2013).Adjuvant chemotherapy and follow-up
The adjuvant chemotherapy consisted of an oral tegafur
agent (OT) or platinum-based chemotherapy (PB). The
criteria for regimen selection were based on a discussion
among the hospital cancer board and enrollment in a
clinical trial. Basically, OT was selected for patients with
stage I (T1bN0M0 and T2N0M0), and PB was selected
for patients with stage II and IIIA [4,13]. The OT regi-
mens consisted of tegafur-uracil (UFT) or S1. The PB
regimens mainly consisted of carboplatin and paclitaxel,
carboplatin and gemcitabine, carboplatin and S1, and
other cisplatin regimens. Postoperative radiotherapy was
not performed. The schedule for follow-up examinations
was arranged on an each individual basis; most of the
patients received medical check-ups and chest X-ray
films or CT scans at least twice per year. The last
follow-up review was performed on June 30, 2014. The
median follow-up duration for the determination ofdisease-free survival (DFS) was 38.6 months (range, 1 to
62 months).
Immunohistochemical staining
The immunohistochemical analyses were performed
using resected, paraffin-embedded lung cancer tissues.
After microtome sectioning (4 μm), the slides were proc-
essed for staining using an automated immunostainer
(Nexes; Ventana, Tucson, AZ, USA). The primary anti-
bodies were used according to the manufacturer’s ins-
tructions (Cox-2: Dako Cytomation, (Glostrup, Denmark)
CX-294, 1:50 dilution). The slides were scored for the
intensity of staining (0 to 3) and the percentages of cells
with scores of 0 (0%), 1 (1% to 9%), 2 (10% to 49%), and
3 (50% to 100%) were determined. The immunohisto-
chemistry (IHC) score (0 to 9) was defined as the pro-
duct of the intensity and the percentage of cells. Cox-2
expression was judged as positive when the IHC score
was ≥4 [12].
Statistical analysis
All the statistical analyses were performed using the
SPSS statistical package (version 17.0; SPSS, Chicago, IL,
USA). Categorical data were examined using the χ2 test.
The prognostic evaluation was performed based on DFS.
DFS was defined as the time until lung cancer recur-
rence or non-lung cancer death. The impact of Cox-2
expression on DFS was evaluated according to the type
of adjuvant chemotherapy (OT or PB). The survival
curves were estimated using the Kaplan-Meier method,
and differences were evaluated using the log-rank test.
Univariate and multivariate analyses were performed
using the Cox proportional hazards model. Two-sided P
values of less than 0.05 were considered statistically
significant.
Results
Clinical characteristics and chemotherapy regimen
The patients ranged in age from 46 to 80 years (mean,
66.9 years). There were 63 men and 34 women. The
pathological stage and histological type at the time of
the final pathological examination are shown in Table 1.
The most frequent histological type was adenocarcin-
oma: 65 patients (67.0%) had adenocarcinoma, 17
(17.5%) had squamous cell carcinoma, 8 (8.2%) had large
cell carcinoma, and 7 (7.3%) had other subtypes. The pa-
tients were classified according to the histopathological
stage as follows: 42 patients had stage I, 27 had stage II,
and 28 had stage IIIA disease. Of the 97 patients, 51
(52.6%) received PB, and 46 (47.4%) received OT. The
most frequent chemotherapy regimen was carboplatin +
paclitaxel in the PB group, and UFT in the OT group.
Five cases using carboplatin + S1 were included in the
PB group.





Age, mean ± SD 66.9 ± 9.0
Histology
Adenocarcinoma 65 67.0
Squamous cell carcinoma 17 17.5
Large cell carcinoma 8 8.2
Adenosquamous carcinoma 2 2.1












IIA + IIB 27 27.8
IIIA 28 28.9
Chemotherapy regimen
Platinum-based agent 51 52.6
CBDCA + paclitaxel 35
CBDCA + gemcitabine 7
CBDCA + S1 5
CDDP + others 4
Oral tegafur agent 46 47.4
UFT 37
S1 9
SD: standard deviation; CDDP: cisplatin; CBDCA: carboplatin;
UFT: tegafur-uracil.
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clinicopathological characteristics
The PB group had a higher proportion of a patho-
logical lymph node status of N1 or N2 than the OT
group (P = 0.009), but no significant associations were
observed between the chemotherapy regimen and pa-
tient age (P = 0.248), tumor size (P = 0.220), or histo-
logical subtype (P = 0.897) (Table 2).
Cox-2 expression status
An immunohistochemical study showed that 56 cases
(57.7%) had a positive Cox-2 expression status. The rateof Cox-2 expression in the PB and OT groups were simi-
lar (58.8% vs. 56.5%) (Table 2).
Prognostic analysis
Among the patients who received OT, the DFS of the
patients with Cox-2 expression was not poorer than that
of the patients without Cox-2 expression (P = 0.617, log-
rank test; Figure 1). On the other hand, among the pa-
tients who received PB, the DFS of the patients with
Cox-2 expression was significant poorer than that of the
patients without Cox-2 expression (P = 0.017; Figure 2).
In a univariate analysis, Cox-2 expression and lymph
node metastasis were predictors of the DFS. Furthermore,
in a multivariate analysis, Cox-2 expression (P = 0.011),
lymph node metastasis (P = 0.030), and vascular invasion
(P = 0.017) were independent predictors of the DFS
(Table 3).
Discussion
Recently, both experimental and clinical studies have re-
vealed that many molecules contribute to the various
biological behaviors of malignant tumors including
NSCLC. New strategies based on a better understanding
of tumor biology are thus needed to maximize the effi-
cacy of current treatments. The associations between
these strategies and the response to chemotherapy have
been investigated, and the selection of effective chemo-
therapy regimens based on the evaluation of these bio-
markers may improve the clinical outcome of NSCLC
patients. PB remains the scaffold upon which combin-
ation chemotherapy regimens are assembled for NSCLC
patients. As a predictor of the efficacy of PB, the intratu-
moral expression of excision repair cross-complementing
group 1 (ERCC1, a major component of the nucleotide ex-
cision repair pathway, is reported to associated with the
responsiveness of patients to cisplatin [14,15]. In addition,
the intratumoral expression of class III β-tubulin is likely
to be associated with the responsiveness to taxanes, such as
paclitaxel and docetaxel [16,17]. Moreover, ribonucleotide-
diphosphate reductase M1 (RPM1) is likely to be associated
with the responsiveness to gemcitabine [18]. On the other
hand, OT is widely used in Japan [19,20]. 5-Fluorouracil
(5-FU)-derived agents, such as UFT and S1, are effective
for patients with NSCLC who have a low expression of
thymidylate synthase (TS) [21]. However, evidence re-
commending the routine clinical use of these agents re-
mains insufficient.
In this study, we investigated the prognostic signifi-
cance of Cox-2 expression among patients with adjuvant
chemotherapy. Several studies have suggested a prognos-
tic and predictive role for Cox-2 expression in NSCLC
[22-25]. In a 2006 meta-analysis of the role of Cox-2 in
NSCLC, a trend toward Cox-2 overexpression as a prog-
nostic factor affecting the survival of patients with






Patients, number 51 46






Squamous cell carcinoma 10 7
Large cell carcinoma 5 3
Adenoaquamous carcinoma 1 1
Pleomorphic carcinoma 2 3
Tumor size (mean), mm 37.7 34.3 0.220
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studies was relatively high [26]. In 2008, Edelman et al.
reported that Cox-2 expression was a significant prog-
nostic factor in patients with advanced NSCLC (Cancer
and Leukemia Group B Trial 30203). Moreover, patientsFigure 1 Kaplan-Meier disease-free survival curves according to cyclowith moderate to high Cox-2 expression had a better
tumor response to a Cox-2 inhibitor (celecoxib) in terms
of a longer median survival period compared with those
not receiving celecoxib [12]. On the other hand, in the
NVALT-4 study performed in 2011, Cox-2 expressionoxygenase-2 expression. Oral tegafur agent: log-rank, P = 0.617.
Figure 2 Kaplan-Meier disease-free survival curves according to cyclooxygenase-2 expression. Platinum-based chemotherapy:
log-rank, P = 0.017.
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when celecoxib was added to chemotherapy. However, in a
subset analysis, patients with squamous cell carcinoma
seemed to perform better when treated with celecoxib [27].
The present study focused on patients who had re-



















P value was calculated by log-rank test. HR: hazard ratio; 95%CI: 95% confidence inexpression was a powerful prognostic factor for patients
who had received PB. Regarding postoperative chemo-
therapy, Cox-2 expression was previously reported not
to be a significant prognostic factor when using UFT
[28]. The results of this previous report were similar to
the results of our study on patients who received UFTe survival in adjuvant chemotherapy with platinum-based
Multivariate
P value HR 95%CI P value
0.639 2.11 0.77-5.82 0.149
0.303 2.38 0.65-8.74 0.191
0.160 1.89 0.70-5.11 0.208
0.011 3.15 1.12-8.85 0.030
0.533 0.82 0.50-1.36 0.453
0.072 3.79 1.26-11.35 0.017
0.024 3.96 1.38-11.38 0.011
terval; SQ: squamous cell carcinoma; Cox-2: cyclooxygenase-2.
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cant prognostic factor when postoperative PB is used
has been previously reported. The reason for the differ-
ence in the effects observed in the PB and OT groups re-
mains unclear. Of interest, the results from a preclinical
analysis showed that a Cox-2 inhibitor enhanced the re-
sponses to chemotherapy with cisplatin or paclitaxel
through the existence of a functional p53-Cox-2 connec-
tion in response to DNA damage [29]. From these pre-
clinical findings and the present reported study, the
combination of PB, but not OT, and a Cox-2 inhibitor
could be promising. Based on these observations and the
present study, we propose that a clinical trial examining
the use of a Cox-2 inhibitor in platinum-based adjuvant
chemotherapy should be conducted.
This study had several limitations that should be con-
sidered when interpreting the results. The retrospective
study design and the relatively small number of enrolled
patients were the major limitations of the present study.
Conclusions
In conclusion, the present study suggests that Cox-2 ex-
pression was a powerful predictor of DFS among pa-
tients who received PB as an adjuvant chemotherapy.
Further study investigating the use of a Cox-2 inhibitor
for adjuvant chemotherapy is needed.
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